#USA #New York #Novo Nordisk #Moore Law #Hims & Hers

Moore Law Takes Action Against Hims & Hers Health Inc.

Moore Law PLLC, a prominent shareholder litigation law firm based in New York City, has announced an investigation into potential claims involving Hims & Hers Health, Inc. This action comes in light of significant developments related to a recent partnership between Hims & Hers and Novo Nordisk, which has raised concerns among investors regarding the company’s practices and legal compliance.

Novo Nordisk Collaboration: A Gamble Gone Wrong?

On April 29, 2025, Hims & Hers unveiled a long-term collaboration with Novo Nordisk with much fanfare, initially touting the immediate availability of packaged offerings that included the FDA-approved medication Wegovy® on its platform. However, just weeks later, on June 23, 2025, the situation took a drastic turn. Novo Nordisk issued a press release proclaiming the termination of its partnership with Hims & Hers, citing severe concerns regarding the alleged deceptive marketing and distribution of unauthorized, fraudulent versions of Wegovy®—a medication used for weight management.

Novo Nordisk's accusations didn't stop there. They raised alarm bells regarding the safety of these said 'knock-off' products, stating that the active ingredients linked to these drugs were sourced from unverified foreign suppliers in China. According to Novo Nordisk, these compounds have never received approval from the FDA and could pose health risks due to the presence of unsafe foreign ingredients. This controversy led to a swift response from investors.

The Impact on Shareholders

As news of the potential misconduct unraveled, Hims & Hers saw a staggering drop in shareholder value. The company’s stock plummeted $22.24, marking a 34.63% decrease, closing at $41.98 per share on the day of the announcement. This dramatic decline prompted many investors to reconsider their stakes in Hims & Hers, ultimately leading to Moore Law's involvement.

Shareholders of Hims & Hers Health, Inc. (NYSE: HIMS) are encouraged to act swiftly. By contacting Moore Law via email, they may be able to pursue avenues for monetary recoveries, corporate governance reforms, reimbursements for losses incurred, and potentially a court-approved incentive award, all with no upfront costs involved. The firm's representation comes under a contingency fee basis, meaning shareholders will not face additional out-of-pocket expenses.

What’s Next for Hims & Hers?

The fallout from the partnership with Novo Nordisk notably raises questions about Hims & Hers’s operational ethics and regulatory practices. As Moore Law delves deeper into the investigation, further disclosures and legal actions might be expected from both sides.

Investors who suspect that they may have been impacted by these developments should consider their options. The ongoing investigation could reveal more about the inner workings of Hims & Hers and the implications of their decision-making processes.

For investors seeking to pursue potential claims or needing more information, Moore Law can be reached at [email protected] or by phone at (212) 709-8245. The firm is prepared to assist those affected by this situation, ensuring that shareholders are informed about their rights and options moving forward.

Conclusion

The circumstances surrounding Hims & Hers Health, Inc. and its partnership with Novo Nordisk serve as a cautionary tale about the complexities of healthcare collaborations and the profound impact they can have on investor trust and stock value. Moore Law PLLC's active investigation signifies the seriousness of the allegations and the need for transparency and accountability in corporate governance. As the situation unfolds, both Hims & Hers and its investors will face critical decisions affecting their futures.